Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1996 to 2010 of 2172 results for technology appraisal

  1. Vismodegib for treating basal cell carcinoma (TA489)

    Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.

  2. Methadone and buprenorphine for the management of opioid dependence (TA114)

    Evidence-based recommendations on methadone and buprenorphine (oral formulations) for managing opioid dependence in adults.

  3. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

  4. Clostridioides difficile infection: antimicrobial prescribing (NG199)

    This guideline sets out an antimicrobial prescribing strategy for managing Clostridioides difficile infection in adults, young people and children aged 72 hours and over in community and hospital settings. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations do not cover diagnosis.

  5. Human Growth Hormone for Idiopathic Short Stature (in children)[ID317]

    Discontinued Reference number: GID-TA11256

  6. Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

    Discontinued Reference number: GID-HST10007

  7. Home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome (HTG735)

    Evidence-based recommendations on home-testing devices for diagnosing obstructive sleep apnoea hypopnoea syndrome.

  8. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

  9. Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma (TA1090)

    Evidence-based recommendations on durvalumab (Imfinzi) with tremelimumab (Imjudo) for untreated advanced or unresectable hepatocellular carcinoma in adults.

  10. Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]

    Discontinued Reference number: GID-TA11205

  11. Masitinib for previously treated moderate Crohn's disease [ID1239]

    Discontinued Reference number: GID-TA11188

  12. Erlotinib in combination with bevacizumab for the maintenance treatment of advanced or metastatic non-small cell lung cancer [ID44]

    Discontinued Reference number: GID-TA11206

  13. Erlotinib in combination with bevacizumab for the second line treatment of advanced or metastatic non-small cell lung cancer [ID43]

    Discontinued Reference number: GID-TA11207

  14. Ovarian (epithelial), fallopian, peritoneal cancer - paclitaxel (encapsulated in XR-17 [ID565]

    Discontinued Reference number: GID-TA11209

  15. Multiple myeloma (untreated) - carfilzomib (with melphalan and prednisone) [ID1133]

    Discontinued Reference number: GID-TA11210